Hinduja Global Solutions (HGS) Q1 26/27 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 26/27 earnings summary
2 Nov, 2026Executive summary
Q1 FY2027 priorities included disciplined execution, AI-embedded engagements, MENA expansion, capability building and cost optimization.
A planned phase-out of a large client engagement and related one-time costs weighed on results; management expects the diversified pipeline to support growth in H2 FY2027.
Financial highlights
Consolidated revenue from operations was ₹1,050.36 crore, down 3.2% QoQ and 0.6% YoY; total income was ₹1,201.16 crore, down 4.3% QoQ and up 2.9% YoY.
Consolidated EBITDA was ₹116.3 crore, down 41.0% QoQ and 27.2% YoY; margin was 9.7%, versus 15.7% in Q4 FY2026 and 13.5% in Q1 FY2026.
Consolidated loss from continuing operations was ₹66.26 crore; total PAT was a loss of ₹66.3 crore, versus a loss of ₹13.6 crore QoQ and profit of ₹11.2 crore YoY. PBT before exceptional items was a loss of ₹52.8 crore.
Interest expense was ₹45.5 crore, versus ₹48.1 crore QoQ and ₹57.9 crore YoY; other income was ₹150.8 crore, up 15.1% YoY.
Standalone revenue was ₹448.36 crore and net loss ₹62.05 crore, compared with ₹462.10 crore revenue and a ₹62.15 crore loss YoY.
Outlook and guidance
Management expects gradual growth and margin improvement through FY2027, with operating leverage returning as volumes normalize and investments commercialize; the diversified pipeline is expected to support H2 growth.
New client engagements typically take 6–8 months to scale; onboarding and training weigh initially, with growth and margin accretion expected before fiscal year-end.
Pipeline demand includes Agentic AI, APA, contact-center modernization and platform services; management sees opportunities in AI-led transformation, platforms and intelligent operations.
Latest events from Hinduja Global Solutions
- Q2 operating EBITDA rose 30% as cost discipline offset muted growth.HGS
Q2 23/24 - Q3 EBITDA surged and PBT turned positive amid digital growth and uncertain demand.HGS
Q3 23/24 - FY2024 operating EBITDA rose 45.8% as AI-led growth advanced amid unresolved tax-search exposure.HGS
Q4 23/24 - One-time costs pressured margins; healthcare-sale gain lifted PAT, with recovery expected from Q2.HGS
Q1 24/25 - UK and macro headwinds cut revenue as technology and AI initiatives advanced.HGS
Q2 24/25 - FY25 PAT included a healthcare-sale gain as strategy pivots to AI-led digital growth.HGS
Q4 24/25 - Q3 EBITDA margin reached 19% as AI-led growth advanced amid near-term revenue pressure.HGS
Q3 24/25 - Margin expansion and digital traction amid softer Q1 revenue.HGS
Q1 25/26 - FY26 EBITDA fell 20.1%; record wins and Project GANGA support growth prospects.HGS
Q4 25/26